ACE and myocardial infarction: Initiating angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) early after acute myocardial infarction (AMI) has been well proven to improve the prognosis of those patients in landmark clinical trials (1–6).